| Sanofi-Aventis (Suisse) SA - Aprovel 150, comprimés pelliculés | | 54250 | | 02 | | Aprovel 150 | | comprimés pelliculés | | C09CA04 | | Irbesartan | | 15.08.1997 | | |
| | Composition | | Comprimé pelliculé: irbesartanum 150 mg, lactosum monohydricum 51 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.092 mg, hypromellosum, silica colloidalis hydrica, magnesii stearas, pellicule: lactosum monohydricum 3.6 mg, hypromellosum, macrogolum 3000, E 171, cera carnauba, pro compresso obducto. | | Packungsbestandteile | | Coated tablets | | | | | Active Agent | Dose | additional_information |
|---|
| Irbesartan | 150 mg | Comprimé pelliculé |
| | BAG: Active Agent | Dose |
|---|
| Irbesartan | 150 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| Carmellosum Natricum Conexum | | | | Cellulosum Microcristallinum | | | | Cera Carnauba | | | | E 171 | | color. | | Hypromellosum | | | | Lactose Monohydrate | 3.6 mg | pellicule | | Macrogol | 3000 | | | Magnesii Stearas | | | | Pro Compresso Obducto | | | | Silica Colloidalis Hydrica | | |
| |
| |
|
